A Randomized, Double-Blind, Placebo- and Active-Controlled, Escalating Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Profiles of Subcutaneous Eflapegrastim in Healthy Japanese and Caucasian Subjects

BACKGROUND: Eflapegrastim (Rolontis(®)) is a novel long‐acting pegylated recombinant human granulocyte colony-stimulating factor (G-CSF). Eflapegrastim has been developed to reduce the duration and incidence of chemotherapy-induced neutropenia in cancer patients using patient-friendly, less-frequent...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeon, Yoomin, Lee, Nora, Baek, Seungjae, Choi, JaeDuk, Jhee, Stanford, Lee, Howard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885935/
https://www.ncbi.nlm.nih.gov/pubmed/34993933
http://dx.doi.org/10.1007/s40268-021-00379-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885935/
https://www.ncbi.nlm.nih.gov/pubmed/34993933
http://dx.doi.org/10.1007/s40268-021-00379-8

Ejemplares similares